1. Scrip
  2. >>Business

Gilead Doesn’t See Big M&A In Near-Term, But Eyes Next-Gen Cell Therapies

 
• By Alaric DeArment

CEO Daniel O’Day highlighted Gilead’s large pipeline and relative safety from patent expirations over the next few years in the company’s Q1 earnings call.

• Source: Shutterstock

Gilead Sciences, Inc. is looking to expand its CAR-T cell therapy offerings beyond currently approved CD19-directed products and an investigational anti-BCMA candidate to include off-the-shelf options and CAR-Ts for autoimmune diseases. But despite kicking off the year with a multibillion-dollar liver disease play with the acquisition of CymaBay Therapeutics, Inc., the company does not see further major acquisitions happening anytime soon.

The Foster City, CA-based drug maker announced its first quarter 2024 earnings on 25 April, reporting total revenues of $6.7bn, a 5% increase over the comparable period in 2023, with increased sales for HIV, oncology and liver disease drugs driving that growth

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

More from Business

Accelerated Approval May Be Out Of Reach For PTC’s Huntington’s Drug

 
• By Joseph Haas

PTC said its updated Phase II data for PTC 518 met the primary endpoint of Huntingtin’s protein reduction, but analysts said there isn’t clear correlation with clinical benefit.

Finance Watch: Unity Lays Off All Employees As It Evaluates Alternatives

 
• By Mandy Jackson

Restructuring Edition: Unity unveiled more Phase IIb data for lead asset UBX1325 along with plans to shed its workforce while seeking a partner for it and other drugs. Also, Ono is consolidating US employees at one site, Entrada is cutting its workforce by 20% and other recent strategic shifts.

Pharma Predicts Modest Impact From Tariffs, But It Depends On What Comes Next

 
• By Jessica Merrill

Drugmakers aren’t expecting a big financial hit from tariffs for now, but a report commissioned by PhRMA suggests the cost of pharma-sector tariffs could be steep.